Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic
Albert Garcia‐Romeu, David J. Cox, Kirsten E. Smith, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107849-107849
Open Access | Times Cited: 144

Showing 51-75 of 144 citing articles:

Evaluation of the rewarding effects of mitragynine and 7‐hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats
Azin Behnood‐Rod, Ranjithkumar Chellian, Ryann Wilson, et al.
Drug and Alcohol Dependence (2020) Vol. 215, pp. 108235-108235
Open Access | Times Cited: 27
Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects
Pietro Brunetti, Alfredo Fabrizio Lo Faro, Anastasio Tini, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 10, pp. 309-309
Open Access | Times Cited: 27
Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature
Jawad Ahmad, Joseph A. Odin, Paul H. Hayashi, et al.
Drug and Alcohol Dependence (2020) Vol. 218, pp. 108426-108426
Open Access | Times Cited: 26
Kratom: A systematic review of toxicological issues
Sarah Kerrigan, Stephanie Basiliere
Wiley Interdisciplinary Reviews Forensic Science (2021) Vol. 4, Iss. 1
Closed Access | Times Cited: 22
Need for Clarity and Context in Case Reports on Kratom Use, Assessment, and Intervention
Kirsten E. Smith, Kelly E. Dunn, David H. Epstein, et al.
Substance Abuse (2022) Vol. 43, Iss. 1, pp. 1221-1224
Closed Access | Times Cited: 14
Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature
Cornel N. Stanciu, Saeed Ahmed, Samantha A. Gnanasegaram, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 5, pp. 509-528
Closed Access | Times Cited: 14
Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis
Elisabeth Prevete, Aleksi Hupli, Shanna Marrinan, et al.
Emerging Trends in Drugs Addictions and Health (2021) Vol. 1, pp. 100007-100007
Open Access | Times Cited: 19
Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)
Chad Hartley, Marilyn N. Bulloch, Scott Penzak
The Journal of Clinical Pharmacology (2021) Vol. 62, Iss. 5, pp. 577-593
Closed Access | Times Cited: 19
How Essential is Kratom Availability and use during COVID-19? Use Pattern Analysis Based on Survey and Social Media Data
Oliver Grundmann, Charles A. Veltri, Diana Morcos, et al.
Substance Abuse (2022) Vol. 43, Iss. 1, pp. 865-877
Open Access | Times Cited: 13
Isolated Kratom Use Disorder Treated with Extended-Release Buprenorphine Taper
Benjamin Swart, Charles Reznikoff, Katie Steen
Journal of Addiction Medicine (2024) Vol. 18, Iss. 5, pp. 602-604
Closed Access | Times Cited: 2
Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety
Jyotshna Kanungo, Barbara C. Sorkin, Julie Krzykwa, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 7, pp. 629-646
Open Access | Times Cited: 2
Kratom use in the United States: a diverse and complex profile
Oliver Grundmann, Jane K. Babin, Jack E. Henningfield, et al.
Addiction (2020) Vol. 116, Iss. 1, pp. 202-203
Open Access | Times Cited: 20
Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study
Antonio Metastasio, Elisabeth Prevete, Darshan Singh, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 19
Kratom (Mitragyna speciosa Korth.) an overlooked medicinal plant in Malaysia
Gregory Domnic, Suresh Narayanan, Nethia Mohana‐Kumaran, et al.
Journal of Substance Use (2021) Vol. 27, Iss. 1, pp. 1-6
Closed Access | Times Cited: 16
Kratom use for depression/anxiety self-management: challenges during the COVID-19 pandemic – A case report
Elisabeth Müller, Thomas Hillemacher, Christian P. Müller
Heliyon (2021) Vol. 7, Iss. 5, pp. e07039-e07039
Open Access | Times Cited: 16
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Yu Kyung Lee, Mark S. Gold, Brian Fuehrlein
Journal of the Neurological Sciences (2021) Vol. 432, pp. 120094-120094
Closed Access | Times Cited: 16
Respiratory effects of oral mitragynine and oxycodone in a rodent model
Jack E. Henningfield, Joseph V. Rodricks, Aaron M. Magnuson, et al.
Psychopharmacology (2022) Vol. 239, Iss. 12, pp. 3793-3804
Open Access | Times Cited: 12
Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy
Norsyifa Harun, Nur Azzalia Kamaruzaman, Zarif Mohamed Sofian, et al.
Neuroscience Letters (2022) Vol. 773, pp. 136500-136500
Closed Access | Times Cited: 11
Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic
David Adzrago, Elizabeth O. Obekpa, Tiffany Suragh, et al.
Drug and Alcohol Dependence (2022) Vol. 239, pp. 109605-109605
Closed Access | Times Cited: 11
Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom
Julia Tobacyk, Brian J. Parks, Nakita Lovelady, et al.
International Journal of Drug Policy (2022) Vol. 108, pp. 103817-103817
Open Access | Times Cited: 11
Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects
Salma Pont-Fernandez, Marina Kheyfets, Jeffrey M. Rogers, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 49, Iss. 1, pp. 85-96
Closed Access | Times Cited: 11
Kratom withdrawal: Discussions and conclusions of a scientific expert forum
Jack E. Henningfield, Marek C. Chawarski, Albert Garcia‐Romeu, et al.
Drug and Alcohol Dependence Reports (2023) Vol. 7, pp. 100142-100142
Open Access | Times Cited: 6
Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors
Katherine Hill, Stephen Gibson, Oliver Grundmann, et al.
Substance Abuse Treatment Prevention and Policy (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 6
Examining the Psychoactive Differences between Kratom Strains
Guido Huisman, Maximilian Menke, Oliver Grundmann, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 14, pp. 6425-6425
Open Access | Times Cited: 6
Lipid profile of regular kratom (Mitragyna speciosa Korth.) users in the community setting
Mohammad Farris Iman Leong Bin Abdullah, Kok Leng Tan, Salbiah Mohd Isa, et al.
PLoS ONE (2020) Vol. 15, Iss. 6, pp. e0234639-e0234639
Open Access | Times Cited: 16

Scroll to top